Viewing
|Videos|February 16, 2023

Case 3: Faricimab in a neovascular nAMD patient with persistent fluid

Dr. Khanani discusses how switching to faricimab helped resolve persistent intraretinal and subretinal fluid in a patient and extended treatment intervals leading to decreased patient burden.

Sponsored by Roche

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Subscribe

Latest CME